Senetek Announces Termination of Invicorp(R) License Agreement With Ardana Bioscience Limited

NAPA, Calif., July 3 /PRNewswire-FirstCall/ -- Senetek PLC (OTC
Bulletin Board: SNKTY), a Life Sciences company engaged in the development
of technologies that target the science of healthy aging, today announced
termination of the Invicorp(R) License Agreement with Ardana Bioscience
Limited ("Ardana"). The Agreement was a license to manufacture, market,
sell and distribute Invicorp(R) in Europe and was terminated pursuant to
the Company's contractual rights, precipitated by Ardana's entry into
voluntary administration on June 27, 2008.

Mr. Frank Massino, Senetek's Chairman and Chief Executive Officer
stated, "We have advised Ardana of the Invicorp(R) License termination and
served demand for return of all related clinical and regulatory data. We
have received a number of inquiries regarding the availability of the
European license and we are confident this will be a valuable and
productive asset in the hands of the right partner".

Invicorp(R), is a highly safe and effective treatment for erectile
dysfunction ("ED"), a condition that affects more than 100 million men
worldwide. Invicorp(R) is expected to capture a significant share of the
moderate-to-severe ED market and become the therapy of choice for
second-line ED treatment. Invicorp(R) has received marketing authorization
in Denmark as well as in England. Additionally, Invicorp(R) has been
approved in New Zealand. Senetek has entered into an exclusive licensing
and collaborative marketing agreement for the commercialization of
Invicorp(R) with Plethora Solutions for the North American market.

About Senetek PLC

Senetek PLC (OTC Bulletin Board: SNKTY) is a Life Sciences company
engaged in the development of breakthrough technologies that target the
science of healthy aging. The Company's extensive research collaborations
have resulted in a strong pipeline of patented compounds and products with
broad therapeutic applications and a leading presence in dermatology.
Senetek collaborates with established specialty pharmaceutical companies in
the final development and marketing of its proprietary products, most
recently resulting in the development of the best-selling anti-aging
product sold in the North American physician market.For more information,
visit the company's website at http://www.senetekplc.com.

This news release contains statements that may be considered 'forward-
looking statements' within the meaning of the Private Securities Litigation
Reform Act. Forward-looking statements by their nature involve substantial
uncertainty, and actual results may differ materially from those that might
be suggested by such statements. Important factors identified by the
Company that it believes could result in such material differences are
described in the Company's Annual Report on Form 10-K for the year 2007.
However, the Company necessarily can give no assurance that it has
identified or will identify all of the factors that may result in any
particular forward-looking statement materially differing from actual
results, and the Company assumes no obligation to correct or update any
forward-looking statements which may prove to be inaccurate, whether as a
result of new information, future events or otherwise.

See Also:

• Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poor's Market Access Program



• Lifeclinic to Feature Latest Health Stations at McKesson's Pharmacy of the Future



• Rosetta Genomics to Present at Collins Stewart Fourth Annual Growth Conference



• Triple-S Management Corporation Schedules Second-Quarter Earnings Release and Webcast



• Sunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference

[Via Healthcare]